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Heart failure patients are burdened with a variety of pharmacologic and self-care 
interventions.  Diuretic therapy and fluid restriction can cause thirst and dry mouth, 
which decrease quality of life and adherence to medical recommendations.  Prior research 
has examined saliva stimulants and substitutes to treat thirst and dry mouth in other 
populations, but has not applied these therapies in heart failure.  We propose that 
chewing gum will decrease thirst to a greater extent than artificial saliva in heart 
failure patients when compared to baseline.  A randomized controlled crossover trial 
between chewing gum and artificial saliva will be conducted with each intervention 
lasting two weeks.  As thirst is a distressing symptom caused by standard heart failure 
care and has gone essentially unaddressed, effective treatment of thirst in this population 






CHAPTER 1: Introduction 
1.1 Background 
Heart failure (HF) affects over 5.1 million Americans and the prevalence of the 
disease is increasing. The American Heart Association projects that the total number of 
Americans living with heart failure will increase 46% from 2012 to 2030.  This disease is 
extremely costly financially as well as in terms of morbidity and mortality. In 2012 alone 
the direct cost of medical care for HF patients of all ages was $20.9 billion, and that 
amount is expected to increase to $53.1 billion by 2030.1 Hospitalization for Acute 
Decompensated Heart Failure (ADHF) is responsible for 80% of this cost, is the leading 
cause of hospitalization in the United States, and is associated with a 50%, five-year 
mortality rate.1,2 Increasing size and age of the population, prevalence of the disease, 
healthcare cost inflation, and high morbidity and mortality has made research on the 
treatment of HF a top priority. 
HF is a chronic and progressive syndrome most often occurring in patients over 
the age of 65 as a result of cardiovascular injury from myocardial infarction or 
hypertension, eventually causing remodeling of the myocardium.3 This results in an 
inability of the ventricles to properly fill with or eject blood, lowering cardiac output to a 
point where there is inadequate blood supply to meet circulatory and metabolic 
demands.2,3   The body responds by up-regulating the sympathetic nervous system, renin-
angiotensin-aldosterone system, and vasopressin axis to increase cardiac output.  Chronic 
activation of these neurohormonal pathways eventually has the opposite effect, with 
excessive retention of fluid and sodium causing a paradoxical decline in cardiac output.2 
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This causes the common signs and symptoms of volume overload that often lead to 
hospitalization such as dyspnea, weight gain, cough, fatigue, and lower extremity edema.3 
Patients with HF are burdened with a substantial number of pharmacologic and 
self-care interventions to remove fluid and prevent ADHF exacerbations.  Medications 
include diuretics to remove excess fluid, angiotensin-converting enzyme inhibitors and 
angiotensin receptor blockers to slow the remodeling process in the ventricles, and beta-
adrenergic blockers to reduce myocardial oxygen demand.  All together, these 
interventions are directed to improve symptoms and survival. Self-care practices are 
emphasized in this population as a way to avoid exacerbation, and these include a low 
sodium and fluid-restricted diet, close monitoring of symptoms and daily weights, 
appropriate response to new onset of symptoms or weight gain, and adherence to 
prescribed treatments, which are often numerous and complicated.3   
For many HF patients, consequences of treatment include secondary symptoms 
that lead to decreased quality of life.  In clinical practice, bothersome thirst is one 
symptom that nurses and clinicians often encounter in HF patients.  HF patients 
experience a unique combination of factors contributing to the symptom of thirst and dry 
mouth. Prolonged neurohormonal activation that occurs in HF, including increased 
vasopressin and angiotensin II, activates central thirst mechanisms.  Diuretics contribute 
to thirst by initiating loss of body water, increase in plasma osmolality, and xerostomia, 
all of which trigger a desire to drink.4,5 Fluid restriction is a long-standing pillar of self-
care in HF, with conflicting evidence on its utility, that is correlated with increased 
perception of thirst. Some recent studies have suggested fluid restriction has no benefit 
over liberal fluid intake in terms of weight loss, physical capacity, hospitalization, or 
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mortality. 6,7,8 Others cite poor adherence to fluid restriction as a common precipitant for 
readmission to hospital, a measure of morbidity in HF.4 In 2013 Philipson et al. 
conducted a randomized controlled trial with 90 stable HF patients and found that 
patients on a fluid and sodium restricted diet had significantly better outcomes in New 
York Heart Association (NYHA) HF functional class and leg edema after 12 weeks 
compared to controls.  Interestingly, thirst was not significantly different between groups 
but this may have been due to insufficient power to detect a difference.8 Despite 
inconclusive results on the importance of fluid restriction, it is a commonly used self-care 
intervention that contributes to the problem of thirst in HF. 
Thirst is described as a sensation causing a powerful urge to drink.5 Xerostomia is 
an element of thirst that may also alter taste, impair dental health, and make speaking 
difficult.6 It is associated with hyposalivation which is a significant risk factor for dental 
disease.9 The existing studies on HF patients have aimed to describe how thirst is 
perceived and determine which subset of this population struggles with it the most. A 
review of the literature suggests that younger age, male sex, higher body mass index 
(BMI), and higher NYHA classification all correlate to higher likelihood of experiencing 
thirst.10   
The greatest impact of thirst in HF that has been noted in the literature to date is 
on quality of life. A descriptive pilot study by Reilly et al. (2010)11 on 25 stable HF 
patients aimed at identifying relationships between thirst, fluid intake, and quality of life 
found that thirst is an issue in patients attempting to follow fluid restricted diets, is 
indirectly correlated with quality of life, and consistently correlates with all subscales of a 
HF symptom scale. A 2013 systematic literature review was conducted by Waldreus et 
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al.5 of original research in HF patients, with thirst as a primary or secondary outcome 
measure, or a patient statement regarding thirst in the results section. They found 
descriptions of thirst in stable HF patients that included terminology such as “enormously 
annoying”, “irresistible”, “unquenchable”, and “preoccupying”.  More importantly, many 
studies in the review reported that patients found the only way to alleviate these feelings 
was to drink more than their fluid restriction allowed. This can lead to a sense of blame 
for their condition and decreased quality of life.  
 
1.2 Statement of the Problem 
The primary barrier to research on thirst is that it is a subjective symptom, 
experienced and described differently by different people.  The Symptom Management 
Model developed at the University of California San Francisco states that to completely 
evaluate the experience of a symptom, the four qualities of distress, duration, frequency, 
and intensity must be assessed12. Currently, there is no framework specifically designed 
to evaluate thirst.  A number of studies have attempted to evaluate thirst in HF, but a 
2014 literature review conducted by Allida et al.12 found that no single study adequately 
assessed all four qualities of thirst, with frequency and distress being the most often 
overlooked.  Moreover, there are only three tools designed to assess thirst, all of which 
rely on self-report, and none are validated specifically for HF.4 These are the Visual 
Analogue Scale (VAS) and the Numeric Rating Scale, which are both commonly used to 
evaluate pain and breathlessness.  The third is a Thirst Distress Scale (TDS), which has 
most commonly been used to evaluate thirst in hemodialysis (HD) patients.12  
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As many as 73% of HF patients struggle with fluid restriction for various reasons, 
and there are currently no intervention studies aimed at reducing or alleviating thirst in 
these patients.5 Providers have suggested that their patients who complain of thirst ingest 
cold drinks, ice chips, peppermint, or buttermilk, and consume less sugar, but none of 
these remedies have been tested for efficacy.4,5 
Thirst management has been most extensively researched in the setting of end-
stage renal disease among patients undergoing HD.  Attention has been focused on 
reducing their thirst and xerostomia to help increase compliance with fluid restriction, a 
self-care requirement that is also prescribed in this population.  Treating these symptoms 
may also help avoid excessive interdialytic weight gain (IWG) and associated 
complications, and to improve quality of life.12. The main categories of interventions 
include saliva stimulants, for example chewing gum, and saliva substitutes. Intervention 
studies examining the efficacy of chewing gum and artificial saliva have been 
inconclusive but have suggested chewing gum, and to a lesser extent artificial saliva, may 
alleviate thirst and dry mouth in HD patients.13,14 These patients preferred chewing gum 
over artificial saliva for its ease of use and taste.13 Neither intervention was found to have 
an impact on IWG or net fluid intake, but this may have been because of the short time 
frame of the interventions. The positive effect of these interventions on alleviating 
xerostomia and thirst has also been found in patients with rheumatic disease and 
malignancy.15,16 Both chewing gum and artificial saliva are financially reasonable 
interventions that have proven to be effective in various populations suffering with thirst, 
and could be an effective treatment for heart failure patients with thirst as well.  
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1.3 Goals and Objectives 
We are proposing a randomized crossover clinical trial, comparing the use of 
artificial saliva and chewing gum in a sample of stable HF patients to test effects on 
subjective thirst and dry mouth.  Mean VAS scores for thirst intensity will be the primary 
outcome measure by which we will compare treatments at the end of intervention 
periods. The TDS and Xerostomia Inventory (XI) will be used to measure thirst distress 
and xerostomia, respectively, as secondary outcomes. Preference for one intervention 
over the other will be assessed with two dichotomous questions.  
 
1.4 Hypotheses 
1. There will be a difference in thirst intensity (VAS), thirst distress (TDS), and 
xerostomia (XI) between the chewing gum group and the artificial saliva group after two 
weeks of each intervention. 
2.  There will be a difference in preference between chewing gum and artificial saliva. 
 
1.5 Definitions 
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CHAPTER 2: Review of the Literature 
2.1 Introduction 
An extensive literature search was conducted between August 2015 and June 
2016 focusing on thirst in heart failure patients.  The aim of the search was to explore the 
underlying pathophysiology of thirst in this population, how the symptom of thirst is 
measured in clinical research, and to uncover which thirst treatments were effective.  
Ovid, Scopus, and PubMed databases were used to access the relevant literature, and the 
search terms utilized included heart failure and thirst or xerostomia or dry mouth, thirst 
or xerostomia or dry mouth and saliva stimulants or saliva substitutes or mastication or 
gum or chew or chewing gum, and heart failure and self care or fluid restriction or 
restrict*. Search criteria were limited to “English language” and produced clinical trials, 
cross sectional studies, prospective cohorts, systematic literature reviews, and meta-
analyses pertaining to HF and thirst, as well as interventions to treat thirst.   
 
2.2 Review of Empirical Studies  
This section will present the literature that has been reviewed pertaining to 
chewing gum and artificial saliva and their effect on thirst.  This relationship has not yet 
been studied in HF patients, so literature from other populations suffering from thirst will 
be utilized.  
2.2a Chewing gum and thirst 
Bots et al. (2004)1 completed a randomized clinical trial examining how eight 
different sugar free chewing gums affect saliva stimulation using a convenience sample 
of 83 healthy dental students from one school in The Netherlands. The group comprised 
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41 men and 42 non-pregnant women at an average age of 25 years, taking no medication 
besides oral contraceptives.  Subjects were randomized into eight different groups to 
receive one of eight different gum flavor and shape combinations including Winterfresh, 
Peppermint, Sweetmint, or Liquorice, and stick, tab, or pellet shapes. Salivary flow 
stimulated by parafilm, a tasteless wax, provided a baseline measurement and chewing 
gum-stimulated salivary flow and pH was measured at intervals up to 10 minutes. 
MANOVA analysis showed no statistically significant differences between chewing 
gums in terms of salivary flow rate; each intervention significantly stimulated salivary 
flow compared to baseline within the first minute of chewing, the average increase being 
187%.  The different gums subsequently exhibited varying rates of declining salivary 
flow over time but after 10 minutes had returned to baseline. Salivary pH increased 
slightly over the 10-minute period, reaching statistical significance in three out of eight 
chewing gums.  However, there was no statistically significant difference in pH change 
between chewing gums.  
 A different group of 112 dental students (61 men 23.2±4.1 years of age and 51 
women 24.1±3.2 years of age) with the same inclusion and exclusion criteria participated 
in a crossover design trial to test preference.  Participants tested three of the different 
chewing gums that were randomly selected for two days each, and afterward completed 
questionnaires with several different VAS on taste, how long participants chewed the 
gum, and willingness to use it long-term. Overall, subjects preferred the Peppermint stick 
and Spearmint pellet gums significantly to other options. 
 This study by Bots et al. (2004)1 suggests equal efficacy of chewing gum to 
increase salivary flow and pH regardless of flavor, shape, weight, and manufacturer, 
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although these variables do seem to influence preference.  Subsequent clinical research 
has offered a choice of gum flavor to participants in an attempt to bolster compliance. 
Since this was a small sample of healthy young adults from one particular school, there is 
limited generalizability to our older HF target population.  It should also be noted that 
Wrigley, a gum manufacturing company that provided the majority of the gum, 
sponsored this research.   
Jagodzinska et al. (2011)2 conducted a three-month prospective study on the 
effect of sugar free chewing gum on thirst, xerostomia, and hydration of 38 stable chronic 
HD patients from a dialysis center in Poland.  This followed a 2005 crossover trial of 
chewing gum vs. artificial saliva by Bots et al.3 that showed chewing gum was effective 
in reducing thirst in HD patients over a shorter intervention period of two weeks.  Those 
included were over 18 years of age, received HD three times weekly for at least three 
months, were clinically stable as determined by daily residual diuresis, and had mean 
IWG ≥1000 g in the two weeks before the study began.  Participants were excluded for 
acute infections, poor control of DM, and orodental conditions that could impair 
chewing.  Baseline characteristics were similar between the study group and reference 
group with the exception of IWG, which was significantly greater in the study group.  
Participants received chewing gum in the flavor of their choice with instructions to 
slowly chew one piece three times daily after meals for a minimum of 20 minutes, and 
throughout the day when they perceived thirst or xerostomia.  They were given a diary to 
record the amount of gum and fluids they consumed daily, and returned empty gum packs 
weekly for assessment of compliance.   
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 Xerostomia and thirst were assessed in a reference group at baseline, and in the 
intervention group at baseline, after three months of intervention, and after one month of 
follow-up using a non-validated 19 multiple-choice questionnaire.   Neither perceived 
xerostomia nor thirst was significantly changed from baseline after the intervention or 
one month follow-up period.  However, for xerostomia management the percentage of 
patients who preferred drinking fluids decreased 26% while those who preferred chewing 
gum increased 250% (p=.04).  Similar trends were seen in thirst management, with a 45% 
decrease in the number of patients who preferred drinking fluids and a 380% increase in 
the number of patients choosing gum (p=.004).   While the majority had chewed gum 
prior to the study, only 10% (n=3) had used it to manage symptoms.  
There are a variety of limitations in this study design that could account for the 
lack of treatment effect.  The use of multiple-choice questionnaire rather than a validated 
tool for thirst or xerostomia decreases internal validity.  Internal validity may also be 
decreased by a learning effect of those who had utilized gum to treat thirst previously. 
The lengthy treatment period could decrease patient compliance compared with other 
similar trials whose interventions lasted a much shorter time, however it did not result in 
a high attrition rate (18.5%).  Despite being from the same HD unit with identical 
inclusion criteria, there was a significant difference in xerostomia and thirst perception at 
baseline between intervention and reference groups, which may reflect poor quality of 
questionnaire or poor randomization. As patients could not be blinded from chewing gum 
use, the study design had to be open which introduces reporting bias.  Side effects from 
therapy including diarrhea, abdominal pain, and decreased appetite were reported in 52% 
of patients, another factor that may have affected compliance. Decreased appetite was the 
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most commonly reported side effect, which is problematic in a largely malnourished HD 
population but could potentially be an added benefit of chewing gum for thirst in other 
settings. Although this was an essentially negative study, the number of patients 
accepting chewing gum as an alternative tool to fluids for symptom management was 
significant.  
Said et al. (2013)4 conducted a quasi-experimental study regarding the effect of 
sugar-free chewing gum on xerostomia, thirst, and IWG in HD patients at the Ain Shams 
University Specialized Hospital in Cairo, Egypt using the DTI (Dialysis Thirst 
Inventory), XI, IWG, and salivary flow rates.  A group of 60 adult patients with end-stage 
renal disease, on HD for three months or more, and stable in terms of dry weight and 
hematocrit were consecutively enrolled and randomized using block randomization 10 
patients at a time into evenly divided intervention and control groups.  Exclusion criteria 
were extensive, and included diabetes mellitus, ischemic heart disease, autoimmune 
disease, malignancy in the oral cavity, microscopic evidence of oral infection, periodontal 
disease, hemodynamic instability, dementia, anxiety, depression, use of chemotherapy or 
radiation, and use of known xerogenic medications including anticholinergics, 
antidepressants, antipsychotics, antihistamines, antiparkinson agents, and diuretics. Data 
were gathered before and after each dialysis session during the two-week trial.  The 
chewing gum group received strawberry and peppermint flavored gum with instructions 
to chew one to two pieces for over 10 minutes, six times daily and whenever the mouth 
felt dry or they felt thirsty.   
Kruskal Wallis tests were used to determine if the four main variables changed 
significantly across six dialysis sessions over a period of two weeks.  XI (0-5) decreased 
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significantly in the intervention group (4.60.6 to 1.80.8, p<0.001) and increased in the 
control group (3.30.7 to 4.00.9, p=0.03).  DTI (0-5) decreased with intervention 
(4.30.6 to 1.90.7, p<0.001) and increased with control (2.31.1 to 4.40.8, p<0.001).  
IWG (kg) also decreased in the intervention group over time (4.41.2 to 1.80.7, 
p<0.001) and increased with no intervention (1.80.5 to 3.01.5, p<0.001).  Salivary flow 
(mL) rate was stimulated by chewing gum (0.40.1 to 0.80.2, p<0.001) and decreased in 
the control group (0.50.2 to 0.40.2, p<0.001).   
Chewing gum as an intervention cannot be blinded, and therefore results of the XI 
and DTI are subject to some degree of reporting bias.  There was a large difference in 
IWG between groups at the first HD session (4.41.2 kg in the study group and 1.80.5 
kg in the control group) despite having no significant difference in baseline dry weight, 
months on HD, age, or sex.  Exclusion criteria were extensive, and eliminated those on 
any type of drug that could cause thirst or xerostomia as well as those with ischemic heart 
disease, both of which are common in the HF population.  This may have increased 
internal validity of the study by eliminating potential confounders, but it also greatly 
limited generalizability.  
In 2013 Fan et al.5 conducted an observational study in No. 5 Hospital of 
Shanghai dialysis center of 42 maintenance HD patients to assess thirst and xerostomia, 
as well as a crossover trial with 11 HD patients over the course of six weeks to test the 
effect that chewing gum versus consuming all liquids through a straw has on the same 
outcomes. Thirst was measured by VAS and DTI, while VAS and XI measured 
xerostomia.  Those included were at least 18 years of age, had been on HD a minimum of 
five months, and had stable dry weight and hematocrit.  Exclusion criteria were 
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hospitalization within the past three months, hemodynamic instability preventing 
sufficient ultrafiltration, dementia, or other terminal disease.  Each intervention lasted 
two weeks with a washout period in between.  Sugar-free mint flavored gum was given 
with instructions to chew a piece for at least 10 minutes, six times daily and additionally 
as desired for feelings of dry mouth and thirst.  Participants were given 3 mm plastic 
straws to drink water through when they had symptoms.    
The use of chewing gum significantly decreased measures of both thirst (VAS 
70.717.1 to 61.122.0, p=0.038 and DTI 19.33.4 to 14.34.8, p=0.000) and xerostomia 
(VAS 54.619.6 to 44.620.0, p=0.001 and XI 32.29.4 to 27.311.7, p=0.001).  The use 
of straw also had an effect on thirst (VAS 70.717.1 to 59.421.7, p=0.016 and DTI 
19.33.4 to 15.65.3, p=0.003) but not on xerostomia. Three-day IWG (kg) decreased 
from a baseline of 3.170.89 to 2.880.65 with chewing gum (p=0.017), and to 
2.940.71 with straw (p=0.049), yet there was no change in daily or two-day IWG. When 
comparing the two treatments directly, the VAS score for xerostomia was significantly 
decreased by the use of chewing gum compared to straw (p=0.06) but there was no 
difference in VAS for thirst, DTI, XI, IWG, or salivary flow rates.  
Unlike prior studies, this study did not show similar trends between salivary flow 
and thirst or xerostomia, suggesting that the cause of thirst in this population is more 
complicated than decreased saliva. The sample size of the crossover trial could also have 
been insufficient to demonstrate the outcomes.  Gum and straws were interventions that 
made it impossible to blind patients, which may introduce reporting bias, although this 
effect is partly mitigated by the crossover design as participants received both. A 
decrease in three-day IWG was a new finding compared with prior studies and would 
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need to be reevaluated with a longer intervention period in the future.  If it is a true 
finding it could have further implications on the importance of treating thirst to improve 
objective outcomes in addition to subjective symptoms, a benefit that has been suggested 
but not supported in previous studies.  
2.2b Artificial saliva and thirst 
Jellema et al. (2001)6 examined the effect of Xialine®, a xantham gum-based 
saliva substitute, versus placebo in a double blind crossover pilot study on radiation-
induced xerostomia and related symptoms in patients with head and neck cancer.  Those 
included had undergone irradiation for head or neck cancer that began at least three 
months before the study, had received a minimum radiation dose of 50 Gy to at least 75% 
of the parotid glands, suffered from subjective xerostomia, and had a WHO performance 
status of 0-2, a common cutoff for research in cancer patients.  Patients were excluded on 
the basis of alcohol abuse and salivary dysfunction due to other causes, including 
medication-induced.  A total of 30 patients from the Netherlands (19 of whom were male, 
mean age of 59) were randomized to receive either Xialine or placebo for the first week, 
then switched and completed a week of the other substance with a one-week washout 
period in between interventions.  Instructions were to use the substance at least four times 
daily. Placebo composition was similar to the intervention but lacked xantham gum, the 
active visco-elastic component of Xialine.  
 A well-validated quality of life questionnaire developed by the European 
Organization for Research and Treatment of Cancer (EORTC) and specific to head and 
neck cancer, the EORTC QLQ-H&N35, was used in this study to evaluate xerostomia 
and related symptoms.  The module contains 35 questions, all of which are rated on a 
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four-point Likert scale and later converted to a scale of 0-100, with higher numbers 
correlating to a higher burden of symptoms. Data were collected at baseline and after 
completion of both treatment arms, and mean changes from baseline were compared 
using repeated measures analysis of variance.  Change from baseline of five or more 
points constituted clinically significant improvement or worsening of symptoms.  
Xerostomia was the symptom with the highest EORTC QLQ-H&N35 score at 
baseline of 84 out of 100, and it improved after Xialine intervention (-14.8) and placebo 
(-17.2) with no significant difference between the two (p=0.78).  The next highest 
baseline score was for sticky saliva at 71, which also improved with Xialine (-10.7) and 
placebo (-11.5) a similar amount (p=0.43).  Problems with speech mean score at baseline 
was 30, and although it was again not a statistically significant between-treatment 
difference (p=0.25), it was demonstrated that Xialine improved it to a clinically 
significant level (-7.1) whereas placebo did not (-0.6).  
Baseline scores were similar at the beginning of each intervention period, 
suggesting the washout period was sufficient and the order of interventions did not affect 
results. This study failed to detect a treatment difference between Xialine and placebo in 
any of the investigated symptoms, but it did show a trend towards Xialine improving 
problems with speech more than placebo.  Both intervention and placebo improved 
xerostomia and the feeling of sticky saliva.  The similar effect in these categories could 
be due to the similar composition of the two treatments, which would suggest that 
xantham gum, considered to be the active ingredient in Xialine, has no additional benefit 
over other saliva substitutes and choice of substitute does not alter results.  The short 
intervention period could also explain their lack of findings. Patients as well as treating 
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physicians were able to be blinded thereby decreasing information bias since the 
interventions compared were both saliva substitutes, packaged identically, and with 
similar composition. The exclusion of patients with salivary dysfunction from 
medications is one criterion that focused this study on radiation-induced xerostomia to 
increase internal validity, but limits generalizability. 
 Alpoz et al. (2007)7 examined the efficacy of Xialine versus placebo to treat 
xerostomia-related symptoms in a single-blind crossover study in patients suffering from 
Sjögren’s Syndrome, an autoimmune disease that decreases the functional capacity of 
salivary and lacrimal glands, causing the main symptoms of dry mouth and eyes.  A 
group of 29 patients age 24-77 (mean=45) being treated at the Ege University Faculty of 
Medicine Department of Rheumatology in Turkey were included in the study.  They had 
diminished salivary function confirmed with salivary flow rates and objective findings of 
xerostomia on exam, did not use alcohol or tobacco, and had not tried any other 
intervention for symptoms besides water. Patients completed questionnaires with VAS 
for 10 different symptoms of dry mouth one hour after first application, and at the end of 
days 1, 7, and 14 for each intervention.  In this crossover design, all participants used 
placebo six times daily for the first 14 days, then after a washout period of seven days, 
everyone completed the study with 14 days of Xialine six times daily.  
 All 10 symptoms of dry mouth decreased with use of Xialine, including burning 
tongue (21.04%), continuous dry mouth (4.78%), painful oral mucosa (3.93%), 
diminished taste (25.12%), difficulty with mastication (37.39%), difficulty swallowing 
(20.93%), the need to sip liquids to aid swallowing (22.95%), difficulty in speaking 
(2.38%), dryness at night or upon awakening (2.54%), and frequent need to moisten oral 
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mucosa (3.24%). With use of placebo, there was improvement of only continuous dry 
mouth (25.42%), difficulty with mastication (27.25%), difficulty swallowing (28.95%), 
the need to sip liquids to aid swallowing (43.98%), difficulty in speaking (39.61%), 
dryness at night or upon awakening (35.24%), and frequent need to moisten oral mucosa 
(33.78%). There was a statistically significant treatment effect favoring Xialine group 
compared to placebo in the categories of overall satisfaction (p=0.011), swallowing 
(p=0.027), daily liquid consumption (p=0.019), mouth burning (p=0.025), the need to sip 
liquids to aid swallowing (p=0.023), and difficulty in speaking (p=0.004). Although 
continuous dry mouth improved in more cases following Xialine administration than 
placebo, this result was not statistically significant (p=0.061).  
 The study by Alpoz et al. (2007)7 was designed as a crossover trial, but there was 
no randomization and all participants received the interventions in the same sequence, 
making it impossible to blind researchers and introducing information bias.  This lack of 
randomization into two different intervention groups also makes it impossible to rule out 
period effect, so there is no guarantee these results are not affected by the order of 
intervention. The discussion states that participants were effectively blinded due to 
similar color, taste, and packaging of the two treatments, however the composition of this 
placebo (plain water with tea) is much thinner than viscous Xialine, making information 
bias possible from participants as well. This study was unique in that they used objective 
means to confirm presence of salivary gland dysfunction, a strategy that is more relevant 
in Sjögren’s Syndrome than other populations. Participants with this disease are typically 
younger women (mean age was 45, sex baseline characteristics were not reported), which 
decreases applicability of these findings to our target population that is primarily 
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composed of older men. 
2.2c Chewing gum and artificial saliva 
In a prospective randomized open crossover study, Davies (2000)8 compared 
efficacy of Saliva Orthana™, a mucin-based artificial saliva spray, with Freedent™ low-
tack, sugar-free chewing gum on xerostomia in patients with advanced cancer.  It was 
conducted in one hospital and one hospice care center in London using both inpatients 
and outpatients complaining of xerostomia. Exclusion criteria included Sjögren’s 
Syndrome or other salivary gland disorders, radiation-induced xerostomia, and cognitive 
impairment.  Forty-three patients (mean age 66, range from 32-87 years, 23 of whom 
were female) were randomized into the two treatment arms for five days of use, followed 
by two days of washout period, and a final five days of the opposite intervention.  The 
instructions for gum and spray were to use them before each meal and at bedtime, as well 
as other times throughout the day if the mouth felt dry. Other saliva stimulants or 
substitutes were not allowed to be used during the study.  A questionnaire and VAS for 
dry mouth were administered at the beginning and end of each treatment period to assess 
efficacy. 
Mean VAS scores in either group were similar at the beginning of the first 
intervention (32.0 mm in the artificial saliva group and 32.5 mm in the chewing gum 
group, p=0.95) as well as the second phase of the study (40.7 mm in the artificial saliva 
group and 31.9 mm in the chewing gum group, p=0.34).  Analysis at conclusion of the 
study showed no evidence of period or carry-over effects (unpaired t-test: P = 0.11). 
Mean changes in VAS scores were similar; +22.4 mm with the use of artificial saliva and 
+30.1 mm with the use of chewing gum (paired t-test: p=0.49). More patients preferred 
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gum (69%) than saliva spray (31%) with the most common reason being a feeling that 
one was more effective than the other, although these data were not determined to be 
statistically significant.   
Internal validity is questionable in this study due to a large dropout rate of 30%, 
the majority of which was due to death or deterioration in condition, a common issue in 
advanced cancer research and likely why the intervention period was kept short. There 
was no difference in the number of side effects reported between groups (five from saliva 
spray, seven from chewing gum, p=0.75), however the three participants that dropped out 
because of side effects were all due to chewing gum (nausea and mouth irritation). The 
article reported baseline characteristics on potential confounders such as the use of 
dentures and drugs that cause xerostomia but did not exclude them, which increases the 
external validity of their results.  Oddly, the VAS scale given to patients in this trial had 0 
symbolizing the “worst imaginable oral dryness” and 100 symbolizing “no oral dryness”, 
which is the opposite of how this common scale is typically implemented.  This could 
have confused participants who were familiar with this type of scale, potentially 
influencing results.   
In 2005, Bots et al.3 conducted a randomized crossover trial with repeated 
measures, comparing the efficacy and preference of Freedent chewing gum versus 
Xialine in HD patients.  A total of 89 patients were randomized to receive one of the two 
interventions to use at least six times daily for two weeks, followed by two weeks using 
the other intervention in the same manner, with a two-week washout period in between.  
Inclusion criteria were at least three months on HD, at least 18 years of age, and being 
mentally and physically capable of completing the study.  After 27% of participants 
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dropped out, a total of 65 patients (42 men, 23 women, mean age 54.65) completed the 
study. IWG, salivary flow rates, XI and DTI were measured at baseline and after each 
treatment period.  
Chewing gum decreased the XI score from 29.9 to 28.1 (-1.8 difference, 
p=0.005).  Saliva substitute decreased the XI score from 29.9 to 29.0 (-0.9), which was 
not a significant change.  This was a 50% greater treatment effect of chewing gum vs. 
artificial saliva on XI (p=0.024).  Perceived thirst as measured by the DTI significantly 
improved with chewing gum (p<0.05) from 16.6 to 15.4 (-1.2) and saliva substitute from 
16.6 to 15.5 (-1.1).  This was an 8% greater treatment effect of chewing gum vs. artificial 
saliva (p=0.015).  IWG and salivary flow were unchanged by either intervention.  Age, 
sex, and dentures had no effect on response to treatment.  At the end of both treatment 
periods, a questionnaire was used to assess efficacy and preference.  Chewing gum was 
significantly superior to Xialine in each category, including ease of use, effect on thirst, 
effect on dry mouth, judgment of taste, benefit received, and willingness to use the 
therapy for a longer time period. In a dichotomous assessment of preference, 60% 
preferred chewing gum and 15.4% preferred Xialine (p<0.001), while the rest did not 
report a preference or had no preference.   
At baseline, data were stratified by gender, age (≤65 or >65), residual urine output 
(yes/no), and full dentures (yes/no), and there were significant differences found in IWG, 
XI, and DTI when looking at age and residual urine output.  Younger age and no residual 
urine output, which correlates with more advanced CKD, were associated with high XI, 
DTI, and IWG.  Some other studies chose to exclude denture wearers, but by including 
them Bots et al.3 was able to show they did not have an effect on response to either gum 
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or saliva therapy. Consistent with the study by Bots et al. (2004)1, giving participants a 
choice of gum flavor did not affect outcomes and is assumed to have increased 
compliance. The results only included data from the 73% of participants that completed 
the study, which would not alter characteristics between groups in a crossover design 
study but may introduce bias. No participant dropped out of the study due to side effects, 
but unpleasant taste, nausea, irritation of the oral mucosa, diarrhea, sensitivity of the jaw 
and teeth, and fatigue of muscles were reported.  
 
2.3 Review of Possible Confounding Variables 
2.3a Demographics 
 Age and sex are basic demographics that are reported in all studies to assess their 
potential influence on results, including those on thirst in HF. In 2011, Waldreus et al.9 
conducted a cohort investigation of thirst in 48 HF patients, 65 years of age or older, half 
of whom were admitted to the hospital with acute decompensated HF, while the other 
half were admitted to the hospital for treatment of an acute illness other than HF.  Thirst 
as assessed by VAS was much higher in elderly patients with worsening HF (median 75 
mm, interquartile range 56-90) compared with acutely ill elderly patients without HF 
(median 25 mm, 11-40; p<0.0001). They found that age, gender, and diuretic medications 
were not significant predictors of thirst in either the HF or control group in this specific 
population of elderly people admitted to the hospital. The same investigators conducted a 
descriptive prospective study in 201410 designed to assess the factors associated with 
persistent thirst in HF patients over an 18-month period following hospitalization for HF 
exacerbation. Persistent thirst was found in 121 (19%) of the total 649 patients, and this 
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subpopulation was significantly younger (mean age 64 years versus 70 years, p<0.01), 
more likely to be male (75%, p<0.01), more likely to be on diuretic medications (99% 
versus 95%, p=0.03), and had a greater number of HF symptoms at 1 month (four versus 
three, p<0.01), a higher mean BMI (29 kg/m2 compared with 27 kg/m2 , p<0.01), and 
more depressive symptoms as assessed by the Center for Epidemiological Studies 
Depression Scale (median total score 14.5 versus 12.0, p=0.02).  Ejection fraction, 
NYHA class, N-terminal pro-B-type natriuretic peptide, presence of diabetes or 
hypertension, and practice of fluid restriction were not significantly different among 
those who suffered from persistent thirst.  
2.3b Fluid restriction 
 Holst et al. (2008)11 conducted a randomized crossover study of 74 patients who 
had improved from NYHA class III-IV HF to a stable condition in order to investigate 
the effects of a fluid restricted diet on thirst and other various outcomes.  Fluid restriction 
and liberal fluid intake (control) interventions lasted for 16 weeks each.  Median sense of 
thirst on VAS at the end of the intervention was 51 mm (interquartile range 16-69) in the 
fluid restricted group compared to 23 mm (6-53) for the liberal fluid intake group 
(p<0.001).  Median VAS score for difficulties to adhere to fluid prescription was 23 mm 
(5-56) with fluid restriction, compared to 6 mm (1-24) with liberal fluid intake (p<0.001). 
 In 2013, Philipson et al. 12 conducted a 12-week randomized controlled intervention 
trial of 97 stable HF patients on daily furosemide - a diuretic, comparing the effect of 
fluid restricted diet with no specific restrictions, on a number of outcomes including 
thirst. In this trial, difference in change between groups in regard to thirst, as measured by 
VAS 1-10mm, was not statistically significant (4.2 to 4.4 during the intervention 
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compared to 4.4 to 5.2 during the control, p=0.06). As stated previously, Waldreus et al. 
(2011)9 also found that the presence of persistent thirst was not correlated with fluid 
restriction. Inconclusive data such as these from the body of literature on the benefits and 
consequences of fluid restriction is why it remains a controversial, although often used, 
self-care measure in patients with HF as well as a possible confounder of thirst 
assessment. 
2.3c Heart failure classification and severity 
 It is expected that the bothersome symptoms of thirst and dry mouth would 
increase in severity in a parallel fashion with disease severity, but this has yet to be 
clearly demonstrated in HF.  Waldreus et al. (2011)9 demonstrated a trend in worsening 
thirst with increased NYHA functional classification in patients over 65 admitted to the 
hospital for ADHF.  However, the same investigators later reported data10 suggesting that 
NYHA class, ejection fraction, and N-terminal pro-B-type natriuretic peptide were 
unchanged between those who suffered from persistent thirst and those who did not. A 
pilot study conducted by Reilly et al. (2010)13 on thirst and quality of life in HF found 
that thirst distress is moderately correlated to all subscales on the Heart Failure Symptom 
Survey.  These consisted of frequency (r = .545, p = .005), severity (r = .538, p = .006), 
interference with physical activity (r = .605, p = .001), and interference with enjoyment 
of life (r = .552, p = .004).  Some studies choose to stratify their data by NYHA class 
while others simply record this information in their baseline characteristics. Thus, all do 





 Preference for chewing gum or saliva substitute may have a confounding effect on 
the self-report scales used to quantify thirst and xerostomia. With these different 
interventions, it is impossible to blind participants to eliminate this effect. The question 
of preference is also closely related to compliance, another potential confounder. 
Therefore, reporting patient preference along with thirst outcomes is of utmost 
importance. The hypothesis of our proposed study is that irrespective of the results of the 
primary outcome, more patients will prefer chewing gum to artificial saliva based on 
similar findings throughout our literature review.2,3,8 
 
2.4 Review of Relevant Methodology 
Detailed methodology of the proposed study is outlined in Chapter 3.  This section 
is designed to provide a review of relevant study methods. It is impossible to compare 
methodology used in studies on the effect of artificial saliva and chewing gum on thirst in 
heart failure patients, as none exist in the literature.  
2.4a Design  
In a 2011 Cochrane review by Furness et al.14 on topical therapies for dry mouth 
management, 29 out of the 36 included studies were crossover designs, with a washout 
period between interventions. Research on thirst lends itself to this study design as it is a 
stable, slowly changing condition, and the topical therapies designed to alleviate it have 
no known lasting effects and are considered reversible in a relatively short time frame, 
especially when a washout period is utilized. An added benefit of this design is that it 
decreases problems with confounding variables between groups, since each participant is 
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included in both arms of the trial, and thereby serves as their own control. This allows for 
statistical analyses that assume randomization, and gives participants the ability to 
directly compare preference. It also has unique characteristics for statistical analysis.  The 
sample size needed to power a study and meet the same criteria in terms of type I and II 
errors is lower than studies with parallel groups, making it a statistically efficient design.  
There are some pitfalls of this type of study as well, some of which can be avoided with 
proper design. There can be unintended effects based on the order of intervention 
(treatment effect), and carry-over effects from one intervention period to another, for 
example, learning the study procedures over time (period effect).  These can be avoided if 
the therapies being tested have short-term efficacy and a long enough washout period is 
used between interventions.  Analysis can be performed after the fact to ensure the results 
are free from these unintended effects.15  
2.4b Setting and selection criteria 
The proposed study will take place in outpatient HF clinics in Connecticut. Adults 
≥ 18 years of age with evidence of structural underlying heart disease who fall into 
NHYA functional class II-IV will be eligible to participate.  Patients included will be in a 
stable condition as determined by lack of symptoms or physical exam findings of fluid 
overload, and no medication adjustments in the preceding two weeks.  Prior studies on 
thirst in this population had participants recruited at time of discharge from 
hospitalization for a HF exacerbation, but as our study aims to capture information from a 
more stable sample, hospitalization within the past month for any reason will be an 
exclusion criterion.11,12,16 Patients who are not able to chew gum, apply a salivary spray, 
or complete written surveys will be excluded. 
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2.4c Interventions 
The most common interventions for thirst are topical and include either saliva 
substitutes (viscous material applied to the oral mucosa in the form of sprays, gels, oils, 
mouthwashes, or pills, also referred to as “palliative care”) or saliva stimulants (lozenges, 
chewing gum, or toothpaste which may contain medication).  Less commonly, 
interventional studies have included acupuncture, electrostimulation, and systemic 
therapy such as oral pilocarpine.14     
 Sugar free chewing gum and artificial saliva spray will comprise the two 
treatment arms in the proposed study.  Sugar free chewing gum contains sugar 
substitutes, such as bulk sweeteners like xylitol, mannitol, and sorbitol, or intense 
sweeteners like aspartame; each of these have been shown to be non-cariogenic.17 A 
number of studies have demonstrated that chewing gum increases salivary flow for a 
limited time due to a number of stimuli it provides, including aroma, flavor, taste, and 
mastication.2 It has also been demonstrated that increased salivary flow enhances the 
buffering ability of saliva, so chewing gum can effectively neutralize the decrease in 
saliva and plaque pH that occurs after meals, thereby combating cariogenic acid 
production.17 As discussed previously, Bots et al. (2004)1 conducted a preliminary study 
on salivary stimulation and preference of eight different chewing gums, seven of which 
were Wm. Wrigley Jr. brand. Each gum, despite flavor and shape, stimulated salivary 
flow to the same extent and for the same time period, but patients had a variety of gum 
preferences.  Based on these results, a number of studies that followed gave participants a 
choice of flavor in the hope of improving compliance, a practice that we will continue in 
the proposed study.2,3 
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Different categories and brands of saliva substitutes have been compared and used 
in various trials, but data remain inconclusive regarding which is the most effective, or if 
there is any benefit to them over placebo.18 Xialine is a specific brand of saliva substitute 
that has been utilized most in the literature reviewed, and this will be used in the 
proposed study.  Like all saliva substitutes, it provides a coating over the oral mucosa to 
help retain moisture.  It contains 0.92% polysaccharide xanthan gum as its active 
ingredient (giving it visco-elastic properties similar to human saliva), as well as sodium 
fluoride for tooth mineralization.3,6  
The intervention period of two weeks per treatment with a two-week washout 
period in-between was chosen, as it was the most common length of intervention and 
washout found in studies with positive results.3-5,7 Longer intervention periods such as 
three months in the case of Jagodzinska et al. (2011)2 and shorter time frames such as one 
week in Jellema et al. (2001)6 or five days in Davies (2000)8 showed no treatment effect 
of intervention versus placebo or between two interventions.    
2.4d Outcome measurement 
The VAS is a scale commonly used to evaluate pain and breathlessness, and the 
one that has most commonly been used in HF to evaluate thirst intensity.  A VAS is 
characterized by a continuous horizontal line from 0-10 or 0-100 mm with verbal 
descriptors on either end, and typically the left side of the line indicates lack of a 
symptom while the right indicates the greatest symptom level possible.7 Waldreus et al. 
(2013)19 and Allida et al. (2014)20 conducted similar reviews of original studies in 
patients with HF using thirst as an outcome measure. In total, five of the 11 studies 
included used the VAS, making it the most common scale utilized. It is commonly 
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employed in other populations suffering from thirst and dry mouth including HD, 
Sjögren’s Syndrome, and head and neck radiation.5,14,21 While it has not been specifically 
validated to evaluate thirst intensity in HF, its consistent use in research for purposes of 
assessing characteristics associated with thirst makes it the best tool to derive a treatment 
effect from in order to calculate sample size, and to assess our primary outcome in the 
proposed study.  
The TDS is a scale that has been validated in HD patients to assess thirst distress, 
defined as the degree to which a person is bothered by thirst or its associated discomfort. 
It was developed in 2002 by Janet Welch22 and is a six-item tool, each with a five-point 
Likert scale where 1 corresponds to strongly disagree and 5 to strongly agree, for a total 
possible score ranging from 6-30.  In the development of the TDS, Welch used a panel of 
experts to establish content validity and a convenience sample of 247 adults receiving 
outpatient HD to test the item pool.  Cronbach’s alpha was 0.78, considered to be 
satisfactory in terms of reliability.  Confirmatory and exploratory factor analysis, as well 
as observed associations between thirst distress, thirst intensity, and IWG supported 
construct validity. While it is not included as part of the TDS, Welch used a VAS for 
thirst intensity in conjunction with TDS for a more global assessment of the symptom.22 
Jacob et al. performed a follow-up study in 2004 which again supported a correlation 
between TDS and IWG in HD patients.23 Due to this evidence of validity and reliability 
in HD, the TDS has been used commonly in this population but can also be found in 
recent articles on HF as this population lacks a specific validated scale.  Reilly et al.13 
used the TDS as the only measurement of thirst in a 2010 pilot study on thirst and quality 
of life in HF with mean of 15.6 (SD 7.7). They reported a moderate correlation between 
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all the symptoms of the Heart Failure Symptom Survey and the TDS: frequency (r = .545, 
p = .005), severity (r = .538, p = .006), interference with physical activity (r = .605, p = 
.001), and interference with enjoyment of life (r = .552, p = .004).13,19 This was the only 
study to use this scale in a 2014 comprehensive review of articles using subjective 
measures of thirst as a primary or secondary endpoint in HF patients conducted by Allida 
et al.20, while four of the six studies included used the VAS. The discussion at the end of 
this review again suggested combining multiple scales for more thorough data.  
 XI is a tool composed of 11 questions relating to the symptom of dry mouth, each 
with a corresponding five-point Likert scale ranging from 1 (never) to 5 (very often).  
These scores are summed to total a final XI score between 11 and 55. It has since been 
validated in HD, but was originally developed and validated in the dental community by 
Thomson et al. (1999).5,24 Initially, 19 questions were compiled to evaluate xerostomia 
based on a combination of literature review, and interviews conducted in a convenience 
sample of four long-term sufferers of xerostomia.  Further analysis divided these 
questions into two different scales, one being the 11-question XI score (Cronbach’s alpha 
of 0.84). The validity of the XI was then tested in a sample of subjects suffering from 
xerostomia who were part of a five-year South Australian Dental Longitudinal Study.  XI 
questionnaires were completed and returned by 649 participants, and were compared with 
a standard single xerostomia question (“How often does your mouth feel dry?” Response 
options: “Never”, “Occasionally”, “Frequently”, “Always”), as well as salivary flow data. 
One-way ANOVA analysis determined that mean XI scores differed significantly 
between each of the four responses on the standard single xerostomia question 
(p<0.0001), with an overall correlation between the two data collection tools of 0.42 
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(p<0.01). Correlation between XI score and resting whole salivary flow rates was low (r= 
-0.05) and not statistically significant. 
This tool has since been widely utilized in a variety of populations, most 
commonly in populations with direct salivary gland involvement such as Sjögren’s 
Syndrome and those with head and neck cancer irradiation.  However, it has also been 
used in research on thirst and dry mouth in HD patients, a population with a more 
complex cause of these symptoms. For example, Bots et al. (2005)3 found a positive 
treatment effect of chewing gum on xerostomia based on the XI.  Salivary flow was 
unaffected, consistent with initial data from Thomson et al.24.  
 Salivary flow rates are commonly measured in studies on thirst as a form of 
objective data, in particular when saliva stimulants such as chewing gum are used.  
Salivary flow is diminished in autoimmune diseases such as Sjögren’s Syndrome and 
with radiation-induced damage to the salivary glands, or with certain medications, but is 
not known to be affected in HD or HF. Said et al. (2013)4 utilized a sample of HD 
patients who demonstrated improved xerostomia, thirst, and salivary flow with the use of 
chewing gum.  However, as stated previously, Thomson et al. (1999)24, Bots et al. 
(2005)3, and Fan et al. (2013)5 found no correlation between XI and salivary flow, and a 
review on xerostomia management by Visvanathan et al. (2009)25 concluded that salivary 
flow rates are highly variable and do not tend to correlate to subjective symptoms.  
Each of the aforementioned scales (VAS for thirst intensity, TDS, and XI) 
evaluates a different part of the symptom in question.  Since there is no clear gold 
standard and each measure contributes unique information, they will each be included in 
our proposed study.  We will however, not include salivary flow as an outcome of thirst 
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since this is an inherently subjective symptom that has not been shown to correlate highly 
with salivary flow rates.  
2.4e Follow-up 
 It has been demonstrated in prior research that the effect of saliva substitutes and 
stimulants occurs quickly, and common practice has been to collect relevant data at 
baseline as well as prior to and immediately following an intervention with no additional 
followup.3,7,8 Jagodzinska et al. (2011)2 was an exception to this practice, and found no 
change in thirst or xerostomia one month following the completion of a chewing gum 
intervention. Therefore, there will be no follow-up period in our proposed study.    
 
2.5 Conclusion 
 Several studies have shown chewing gum to be effective at alleviating thirst and 
xerostomia due to a variety of causes in different populations.2-5,7,8 A more limited body 
of research has shown that saliva substitutes may alleviate these symptoms as well.3,6-8 
There were two studies reviewed that provide a direct comparison of these interventions.  
Davies (2000)8 found that both Saliva Orthana salivary substitute and sugar-free chewing 
gum significantly alleviated thirst as measured by VAS in advanced cancer patients, with 
no between-treatment difference.  There was an overall preference for chewing gum, but 
this was not a statistically significant finding.  Bots et al. (2005)3 found that only chewing 
gum decreased xerostomia significantly, and there was a 50% greater treatment effect of 
chewing gum over Xialine on the XI.  For thirst, both interventions significantly 
decreased the DTI score but there was still a significant 8% greater treatment effect of 
chewing gum over artificial saliva.  In that study, preference for chewing gum was found 
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to be statistically significant. Due to the demonstrated lack of interventional studies at 
alleviating thirst in HF, our proposed study will integrate data from clinical trials in other 
populations with background information on the problem of thirst in HF in order to 
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CHAPTER 3: Study Methods 
3.1 Study Design 
 The proposed study will be a prospective, randomized, single-blinded crossover 
study comparing the efficacy of Freedent
 
sugar-free chewing gum vs. Xialine salivary 
substitute spray in decreasing thirst and dry mouth in stable adult HF patients suffering 
from these symptoms.   
 
3.2 Study Population and Sampling 
 A sample of 120 volunteers will be recruited from the outpatient HF clinics of 
Yale-New Haven Hospital, Bridgeport Hospital, Hartford Hospital, and the University of 
Connecticut Health Center. These clinics combined serve over 1,000 HF patients. 
Patients who report the symptom of thirst or xerostomia, meet the criteria listed below, 
and are willing to participate in the study will be enrolled.  
Inclusion criteria include ≥18 years of age, previous diagnosis of HF documented 
in the electronic medical record, NYHA functional classification II-IV, and willing and 
able to complete survey instruments.  Exclusion criteria include current signs or 
symptoms of volume overload, medication adjustment in the prior two weeks, 
hospitalization for any reason in the prior month, current use of methods besides water 
for thirst or xerostomia symptom management, Sjögren’s Syndrome or other salivary 
gland disorder, prior radiation for head or neck cancer, inability to chew gum or 
personally apply saliva spray, and non-English speaking or reading. Individuals who have 
had medication adjustments in the prior two weeks or been hospitalized in the prior 
month will be re-contacted after the requisite time period has passed. 
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3.3 Subject Protection and Confidentiality 
 Protocol application will be submitted to the Yale Human Investigation 
Committee (HIC) and the Yale Institutional Review Board (IRB) for study approval.  
Upon approval, letters will be sent to each collaborative site for study protocol approval 
via their own institution’s IRB.  Approval letters will be returned and kept on file at the 
Yale HIC.  All members of the research team and outside consultants involved in the 
study will complete the Health Insurance Portability and Accountability Act (HIPAA) 
privacy training and the Yale Human Subjects Protection Training prior to study 
initiation.  Only after all of these requirements have been met will the study begin. 
 Identity and health information of participants will remain confidential. HIPAA 
policy will be strictly enforced, and each participant will be assigned a unique number 
with no personal identifiers, by which they are identified throughout the entire study.  
Written informed consent will be obtained, following standard IRB guidelines. 
(Appendix J).  
 
3.4 Recruitment 
In each participating center, flyers indicating the purpose of the study with contact 
information for a research associate responsible for telephone screening will be posted in 
the waiting area and examination rooms (Appendix A). Telephone screening will begin 
by confirming that the patient feels thirsty or feels their mouth is dry.  A positive 
response to either of these questions will trigger application of the inclusion and 
exclusion criteria to determine eligibility.  If eligible, potential candidates will be 
provided with the informed consent form.  Given the combined numbers of patients seen 
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weekly in the designated practices, we anticipate that study recruitment will last for 
approximately 26 weeks. 
 
3.5 Study Variables and Measures 
3.5a Independent variables 
 Two interventions will be directly compared in this study: 1) Freedent
 
(Wm 
Wrigley Jr Co., Chicago, IL, USA), a low-tack, sugar-free chewing gum, will be provided 
to patients with a choice of three flavors (Sweetmint, Winterfresh, and Peppermint) to 
optimize compliance, with instructions to use one to two pieces of gum at a time, at least 
four times daily (before each meal, before bedtime, and any other time they have 
symptoms), chewing at least 10 minutes each time; and 2) Xialine (Lommerse Pharma 
B.V., Oss, The Netherlands), a polysaccharide xantham gum-based salivary substitute 
with visco-elastic properties similar to human saliva, will be provided in spray bottle 
(50mL) form, with instructions to apply the spray to coat the oral mucosa at least four 
times daily (before each meal, before bedtime, and any other time they have symptoms).  
The use of interventions for thirst other than those provided, or water, will be 
discouraged.   
3.5b Dependent variables 
 The primary outcome of the proposed study will be change in thirst intensity, and 
the VAS will be the primary outcome measure to compare the effect of each treatment 
(Appendix D).  The VAS is a horizontal line 100 mm in length with the left end 
indicating absence of thirst and the right end indicating the highest intensity of thirst.  
Patients will mark the line at the point that most accurately represents their perception of 
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the symptom in that moment, and the distance in mm from the left end of the scale will 
be used as the VAS score.  
The TDS will be used to measure thirst distress (Appendix E), and the XI will 
measure xerostomia (Appendix F), both as secondary outcomes.  
Each scale will be administered at baseline and before and after each treatment 
period, for a total of five assessments over time. Finally, preference for treatment will be 
assessed at the completion of the second intervention period with a series of two 
dichotomous questions; “Do you have a preference for either chewing gum or artificial 
saliva?” (yes/no), followed by “Which do you prefer?” (chewing gum/artificial saliva) if 
the initial response is “yes” (Appendix B).  
3.5c Baseline variables 
Additional variables to be collected at baseline will include age, gender, race, 
NHYA functional classification, alcohol/cigarette/denture use (yes/no), diuretic 
medication (yes/no), and fluid restriction (yes/no). (Appendix B) 
 
3.6 Methodology Considerations 
3.6a Assignment of Interventions 
 Assignment of participants to either chewing gum or artificial saliva for the initial 
intervention period will be accomplished via computer-generated random numbers, 
assigning participants in a 1:1 ratio to either order of interventions.  An independent 
researcher who is not otherwise affiliated with the study will be responsible for this 
process.  The initial intervention will last for a period of two weeks, followed by a 
washout period of two weeks in which participants do not use either intervention, and 
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finally each participant will complete another two-week period of the other intervention 
to which they were not originally randomized.  
3.6b Blinding of Intervention 
 Due to the nature of the different treatment arms, blinding of participants to the 
order in which they receive interventions is not feasible.  All data collectors will be 
blinded to condition. Participants will be instructed to not discuss treatment allocation 
with one another or members of the research team.  
3.6c Blinding of Outcome 
 This study will utilize single blinding, as all researchers collecting and assessing 
data will be blinded to the order of intervention participants received.  
3.6d Adherence 
 Adherence to treatment will be assessed at the end of each intervention period 
using a questionnaire, for a total of two adherence assessments (Appendix C). The 
questionnaire will also ask participants to record any tools, other than the gum or spray 
provided, that they used to treat thirst or xerostomia during the trial. Due to the benign 
nature of the proposed interventions, few adverse events are expected but any that occur 
will be recorded and monitored with the adherence checkpoints.  These will be reported 
in list form in the final results.   
 
3.7 Data Collection 
 Initial collection of baseline data at the beginning of the study will be 
accomplished by a combination of self-administered questionnaires, patient interviews, 
and medical record review to ensure accuracy of information obtained.  Age, gender, 
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race, use of alcohol, use of cigarettes, use of dentures, and practice of fluid restriction 
will be obtained upon patient interview. Diuretic use will be assessed by a combination of 
medical record review and patient interview to ensure there is a prescription as well as 
adherence in taking the medication before answering “yes” to this question.  To ensure 
consistency, one blinded researcher will be responsible for determining NYHA functional 
classification based on patient interview for all participants as this involves some 
subjectivity (Appendix G). Data regarding thirst and xerostomia will be collected by self-
administered questionnaire at baseline and before and after each treatment period for a 
total of five data points over time. The two questions regarding preference will be 
administered once at the completion of the second intervention period.  
 
3.8 Sample Size Calculation 
 The study will utilize a two-tailed test and alpha of 5%, beta of 20%, and power 
of 80%.  Mean score on the VAS will be compared between the two treatments using 
values assessed at the end of the respective treatment conditions.  Assuming a 10-point 
difference on the primary outcome between interventions, power analysis indicates the 
need for 200 participants.  However, when a conversion is completed to account for the 
statistical efficiency of a crossover design, the result is a sample size of 50 participants 
per treatment arm, for a total of 100 participants.  A dropout rate of 20% is expected 
based on previous research.  When this is taken into account, the adjusted sample size 
requires 60 participants per treatment arm, for a total of 120 participants.  Additional 




  We assume the absence of order effects given that, 1) each treatment is 
known to not have carryover effects on any of the dependent variables, and 2) we are 
utilizing a washout period between implementation of treatments.  We will nonetheless 
test whether washout is successful by comparing values for each dependent variable at 
the end of baseline vs. the end of washout (Appendix H).1  
Assuming that washout is successful, a two sample t-test will be used to compare 
the values for each dependent variable (e.g., VAS thirst) at the end of the treatment 
conditions.  If however we find that washout was not successful, we will utilize change 
scores as the dependent variable (e.g., change in VAS thirst from end of initial baseline to 
end of first treatment, end of washout to end of second treatment). These change scores 
will then be combined in t-test comparisons of the two treatments. Superiority of either 
treatment over the other will be demonstrated by a significant t-value.  Chi-square 
analysis will be used in the same manner for the dichotomous dependent variable, 
treatment preference.   
Additional, exploratory analyses will be conducted to determine whether subject 
level variables (e.g., gender, race, age (≤65 or >65), NHYA functional classification, 
alcohol/ cigarette/ denture use (yes/no), diuretic medication (yes/no), and fluid restriction 
(yes/no)) influence superiority of one treatment vs. the other. Given the categorical nature 
of these variables, chi-square tests will be used.  In the case of missing data, the analysis 
will only include results from those participants who completed the entire study protocol 
in an effort to maintain equality in sequence groups, although all of the available data will 
be presented in the document.   
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3.10 Timeline and Resources 
 Recruitment will begin in January of 2017 and is expected to take about 26 
weeks.  The study will be initiated in a rolling manner, and analysis will be completed 
immediately after all 120 participants have completed the study.  
 The Principal Investigator of this study will be Matthew M. Burg, PhD and Co-
Principal Investigator will be Alison Robb, PA-SII.  One research associate will be 
needed to field telephone calls in order to screen and enroll participants. One independent 
researcher will be responsible for the computer-generated randomization and allocation 
process, and will not be involved in any other aspect of the study.  One blinded assessor 
will collect all data and outcome measurements throughout the study. A statistician not 
affiliated with the study in any way will be consulted to assist with data input and 
analysis.  Required equipment will include the chewing gum and artificial saliva, 
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CHAPTER 4: Conclusion 
4.1 Advantages and Disadvantages 
 The proposed prospective, randomized, single blinded crossover study comparing 
the effect of chewing gum vs. artificial saliva on thirst and xerostomia in HF patients 
would be the first of its kind and thus fill a gap in the literature. Since there is no tool 
validated to measure thirst or xerostomia in HF, three different self-report scales will 
quantify patient perception of different aspects of the complex problem of thirst, 
providing a more comprehensive look at the symptom than previous studies. We elected 
to forego objective measurements utilized in similar research with other populations as 
they did not specifically apply to the disease process of HF, have not been proven to 
correlate with symptoms, and distract focus from personal perception of thirst and its 
quality of life implications.  A single, validated tool to comprehensively evaluate the 
symptom of thirst in HF would be a crucial step forward and should be addressed prior to 
conducting research subsequent to this study.   
 Frequency and length of interventions were estimated from previous studies that 
demonstrated a positive effect of chewing gum and/or artificial saliva, and tailored to 
maximize treatment effect while minimizing lapses in adherence and attrition rates.  
Since utilization of these interventions is intended to be long-term in stable HF patients, 
the short intervention period may be a limitation of the study. Besides unstable clinical 
condition and NYHA class I functional capacity (patients with cardiac disease but 
without resulting limitation of physical activity), everyone who reported thirst or 
xerostomia at initial screening and was able to utilize both interventions and complete the 
outcome measurement surveys was included in the study.  The inclusive nature of our 
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criteria introduces multiple possible confounders, but allows excellent generalizability to 
the general HF population. The multicenter nature of our study adds to external validity 
as well. Diuretic therapy and fluid restricted diets are two examples of important 
confounding variables specific to our population; these will be assessed at baseline and 
not serve as exclusions in this first trial of its kind. Studies examining the effect of 
interventions for thirst while stratifying by these variables should be a focus in future 
trials. 
 Crossover study design is consistently utilized in the literature to compare efficacy 
of saliva stimulants and substitutes with one another, or with placebo.  Potential 
limitations of this design include doubling the time frame, carryover effects between 
treatments, and failure to use statistical analysis appropriate for the design, but these were 
all accounted for in our initial design and analysis process.  The numerous advantages of 
this design include direct comparison of the chosen interventions, statistical efficiency, 
and limiting of confounding variables by having each participant serve as his or her own 
control.  In addition, the short-term effect of our interventions makes it likely that the 
order in which they are utilized will not affect results.  These considerations make 
crossover design the best option for our study. 
 A disadvantage of this study is the wide availability and use of one of the 
interventions, namely chewing gum. While patients specifically utilizing a substance 
other than water for thirst or xerostomia treatment will be excluded from study 
participation, some patients will have used chewing gum to treat their thirst in the past.  
This may introduce reporting bias and has the potential to skew preference towards 
chewing gum, a trend found in previous studies, based on familiarity alone. Although 
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chewing gum is readily available to the public, explicit instructions to avoid using either 
intervention outside of its assigned two-week intervention period will be given, and 
verified with the adherence questionnaire.   
 
4.2 Clinical and Public Health Significance 
 Over 5.1 million Americans have a diagnosis of HF, a number that is increasing as 
the population ages, and many of these patients experience the symptoms of thirst and 
dry mouth.1,2 Topical therapies such as saliva substitutes and stimulants have been shown 
to be effective and safe for treating thirst in other populations, and would be simple, cost-
effective solutions to this problem in our target population.  Willingness to utilize a 
therapy long-term is essential as the benefits of these interventions are short-lived, so 
assessment of preference is just as important, if not more important, than data 
determining which method decreases thirst to a greater extent.  It is our hope that 
targeting this long-overlooked symptom in a stable HF population will improve their 
symptoms and quality of life. Further implications of these interventions on compliance 
with diuretic medications and fluid restricted diets, and ultimately on hospitalization 
rates, must be examined after a comprehensive, validated tool for thirst in HF has been 
formulated.2,3 As it stands, research on therapies designed to provide relief to HF patients 
suffering from thirst are long overdue, and our study aims to meet this need as well as 
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APPENDIX A: Recruitment Flyer 
Many heart failure patients suffer from   
thirst or dry mouth… 
 




If you are interested in participating in a short study to test 
simple approaches to treating these symptoms WITHOUT 
taking more pills, please call our research assistant at: 
315-247-1566 
 




APPENDIX B: Data Collection Form 
Study Title: Chewing gum and saliva substitute for the treatment of thirst in heart 
failure: A crossover trial 
Principal Investigators: Matthew M. Burg, PhD and Alison Robb, PA-SII 
Participant Identification #: _____________________ 
Age: _____________________ 
Gender:     M     F     (Circle one response) 
Race: _____________________ 
Use of alcohol:     Y     N  
Use of cigarettes:     Y     N  
Use of dentures:     Y     N  
Fluid restricted diet:     Y     N  
Diuretic therapy:     Y     N  
NYHA functional classification:     II     III     IV      
                                                       VAS (0-100)         TDS (6-30)          XI (11-55)
Baseline: 
Start of intervention #1:  
End of intervention #1:  
Start of intervention #2:  
End of intervention #2: 
Do you have a preference for one intervention over the other?     Y     N 
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If yes, which do you prefer?            Chewing gum            Artificial saliva
APPENDIX C: Adherence Assessment 
Participant Identification #: _____________________ 
In your responses, please do not include any information that would indicate which 
intervention you have been using for the past two weeks, or the order in which you 
received interventions 
 
Intervention Period #1 
1. In the past two weeks, how many days did you fail to use the intervention as 
prescribed? ____________________________________________________________ 
2. In the past two weeks, have you forgotten to take the intervention with you when you 
left the house? __________________________________________________________ 
3. Did you use the intervention as prescribed yesterday? _________________________ 
4. What other tools (besides water) have you used to treat your thirst and/or dry mouth in 
the past two weeks? ______________________________________________________ 
 
Intervention Period #2 
1. In the past two weeks, how many days did you fail to use the intervention as 
prescribed? ____________________________________________________________ 
2. In the past two weeks, have you forgotten to take the intervention with you when you 
left the house? __________________________________________________________ 
3. Did you use the intervention as prescribed yesterday? _________________________ 
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4. What other tools (besides water) have you used to treat your thirst and/or dry mouth in 
the past two weeks? ______________________________________________________ 
APPENDIX D: Visual Analogue Scale (VAS) 





































Response options: Strongly disagree (1), moderately disagree (2), neutral (3), 
moderately agree (4), strongly agree (5) 
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APPENDIX G: New York Heart Association 





























APPENDIX I: Sample Size Calculation 
   Sample size calculation, unadjusted for study design 
 
This software developed by David Schoenfeld, Ph.D. (dschoenfeld@partners.org), with support from          




APPENDIX J: Informed Consent Form 
COMPOUND AUTHORIZATION AND CONSENT FOR PARTICIPATION IN 
THE CHEWING GUM AND ARTIFICIAL SALIVA IN THE TREATMENT OF 
THIRST RESEARCH TRIAL 
 
YALE UNIVERSITY SCHOOL OF MEDICINE 
 
Study Title: Chewing gum and saliva substitute for the treatment of thirst in heart 
failure: A crossover trial 
Principal Investigator: Matthew M. Burg, PhD; Alison Robb, PA-SII 
 
Invitation to Participate and Description of Project 
 
You are invited to take part in a research study designed to look at the effectiveness 
of chewing gum and artificial saliva on treating thirst in stable heart failure patients. You 
have been asked to take part because you have a diagnosis of heart failure, are clinically 
stable with a NYHA functional classification of II-IV, and reported the symptom of “thirst” 
or “dry mouth”. This study will be enrolling approximately 120 participants from four 
different heart failure clinics in the state of Connecticut. 
In order to decide whether or not you wish to be a part of this research study you 
should know enough about its risks and benefits to make an informed decision.  This 
consent form gives you detailed information about the study, which a member of the 
research team will discuss with you.  This discussion should go over all aspects of this 
research: its purpose, the procedures that will be performed, any risks of the procedures, 
possible benefits and possible alternative treatments. Once you understand the study, you 
will be asked if you wish to participate; if so, you will be asked to sign this form. 
 
Description of Procedures 
 
 If you are interested in participating, you will be asked questions about your health 
and habits to determine if you are eligible.  Information collected will include your age, 
gender, race, functional capabilities and symptoms, other medical conditions current and 
prior, medications, fluid intake, and use of cigarettes, alcohol, and dentures.  Before the 
study begins you will meet with a member of the research team who will instruct you to 
complete three different questionnaires to assess your level of thirst and dry mouth.  
 Everyone will have 2 weeks of each treatment, namely chewing gum and artificial 
saliva.  The order in which you receive these interventions will be randomly assigned in 
order to have the same number of participants in either intervention group at a time.  After 
the first intervention period, there will be a 2-week “washout” period during which you 
will not use any tool to help with dry mouth.  The purpose of this is to ensure the effect of 
the first treatment you used does not carry over when you begin the next.  During the two, 
2-week intervention time periods you will utilize the gum or saliva spray before each meal 
and before bedtime, as well as any other time during the day when you need it. We will 
require that you complete the three aforementioned surveys a total of four more times 
during the trial: before and after each 2-week intervention period.  You will also be asked 
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to complete a form describing how well you adhered to using the treatments at the end of 
each intervention time period. 
 The researcher collecting information from you via these surveys will not know 
which intervention you are currently using.  We ask that you do not disclose this 
information to them, or to other participants.  This is an important aspect of clinical 
research called “blinding”, which helps to ensure that the information we collect is free 
from any bias, whether intentional or unintentional.  You should be aware that once the 
trial begins, you will only be identified by a specific number that holds no personal 
identifying information.  Although you are agreeing to allow the primary research team 
access to your medical record for verification purposes, everyone involved will have been 
trained on The Health Insurance Portability and Accountability Act (HIPAA) laws and 
these will be strictly enforced to ensure your privacy.   
A description of this clinical trial will be available on 
http://www.ClinicalTrials.gov, as required by U.S. Law. This web site will not include 
information that can identify you. At most, the web site will include a summary of the 
results. You can search this web site at any time. 
 
Risks and Inconveniences 
 
 It is important to know that you have the right to discontinue participating in this 
trial at any time. The risks and side effects associated with these interventions are minimal 
and include nausea, stomach upset, jaw tiring, and worsening or non-improvement of 
symptoms.  None of these negative events are life threatening or permanent. Staff will be 
on hand to field any questions or concerns you may have and to document any side effects 
you wish to report.   
 As with all studies, there is a small risk of loss of confidentiality.  The procedures 
in place to prevent this have been previously mentioned and every effort will be made to 
keep your information confidential, however this cannot be guaranteed. 
 Utilizing the interventions as instructed, and presenting for a total of five in-person 
meetings for data collection are the main inconveniences you will be faced with.  The 




 Benefits of participating in this study may include improvement of the thirst 




 The chewing gum and saliva spray will be provided at no cost to the participant.  
There is no direct compensation offered to those who agree to participate.  You can expect 
a minimal expense to be incurred for traveling to your usual heart failure clinic a total of 





            There are no validated or well-studied options for thirst symptom management.  
Some home remedies used by other patients (besides drinking water) include drinking 
buttermilk or sucking on ice or hard candy.  We are focusing this study on the chosen 
interventions because we believe they have the potential to be more effective than other 
options, without increasing the amount of water you take in daily, a common concern in 
patients with heart failure.    
 
Confidentiality and Privacy 
 
           Under no circumstances will your information be released to outside parties 
without your explicit consent.  Any identifiable information that is obtained from you 
during the course of this study will remain confidential and will only be disclosed without 
your explicit consent in the case of abuse or reportable diseases, as required by law.  All 
data collection forms and questionnaires will be kept in a locked file cabinet in the locked 
office of the principle investigator.  After all data has been analyzed, paper records will 
be shredded and destroyed in accordance with HIPAA requirements.  When the results of 
this research are published or discussed in any forum, no information will be included 
that would reveal your identity unless you specifically consent to this.  Representatives 
from Yale University, the Yale Human Research Protection Program and the Yale Human 
Investigation Committee (the committee that reviews, approves, and monitors research on 
human subjects), who are responsible for ensuring research compliance, may have access to 
your information during the course of the study.  These individuals are required to keep all 
information confidential.  
You have the right to review and copy your health information in your medical 
record in accordance with institutional medical records policies.  
This authorization to use and disclose your health information collected during your 
participation in this study will never expire. 
 
In Case of Injury 
 
If you are injured while on study, seek treatment and contact the study doctor as 
soon as you are able. Yale School of Medicine and Yale New Haven Hospital do not 
provide funds for the treatment of research-related injury.  If you are injured as a result of 
your participation in this study, treatment will be provided.  You or your insurance carrier 
will be expected to pay the cost of this treatment.  No additional financial compensation 
for injury or lost wages is available. 
 
You do not give up any of your legal rights by signing this form. 
 
Voluntary Participation and Withdrawal 
 
Participating in this study is voluntary. You are free to choose not to take part in 
this study.   Refusing to participate will involve no penalty or loss of benefits to which 
you are otherwise entitled (such as your health care outside the study, the payment for 
your health care, and your health care benefits).  However, you will not be able to enroll 
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in this research study and will not receive study procedures as a study participant if you 
do not allow use of your information as part of this study. 
If you do become a subject, you are free to stop and withdraw from this study at 
any time during its course. To withdraw from the study, you can call a member of the 
research team at any time and tell them that you no longer want to take part.  This will 
cancel any future appointments. The researchers may withdraw you from participating in 
the research if necessary due to worsening medical condition, development of serious 
side effects, or subject non-compliance. 
Withdrawing from the study will involve no penalty or loss of benefits to which 
you are otherwise entitled.  It will not harm your relationship with your own doctors or 
with Yale School of Medicine or Yale-New Haven Hospital. 
You may withdraw or take away your permission to use and disclose your health 
information at any time. You may withdraw your permission by telling the study staff or 
by writing to the principal investigator. If you withdraw your permission, you will not be 
able to stay in this study. When you withdraw your permission, no new health 
information identifying you will be gathered after that date.  Information that has already 
been gathered may still be used and given to others until the end of the research study, as 




We have used some technical terms in this form.  Please feel free to ask about 
anything you don't understand and to consider this research and the consent form carefully 
– as long as you feel is necessary – before you make a decision. 
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Authorization and Permission 
 
I have read (or someone has read to me) this form and have decided to participate 
in the project described above.  Its general purposes, the particulars of my involvement and 
possible hazards and inconveniences have been explained to my satisfaction.  My signature 
also indicates that I have received a copy of this consent form. 
 
By signing this form, I give permission to the researchers to use information about 
me for the purposes described in this form.  By refusing to give permission, I understand 
that I will not be able to be in this research.  
 
Name of Subject:_____________________________ 
 
      




   
___________________________________________ ___________________ 
Signature of Principal Investigator  Date 
                                      or 
___________________________________________ ___________________ 
Signature of Person Obtaining Consent  Date 
 
If after you have signed this form you have any questions about your privacy 
rights, please contact the Yale Privacy Officer at 203-432-5919. 
 
If you have further questions about this project or if you have a research-related 
problem, you may contact the Principal Investigators Matthew M. Burg, PhD at 203-932-
5711 or Alison Robb, PA-SII at 315-247-1566.  If you would like to talk with someone 
other than the researchers to discuss problems, concerns, and questions you may have 
concerning this research, or to discuss your rights as a research subject, you may contact 
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